Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06944873

Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases

Inflammatory bowel diseases, Crohn's disease and haemorrhagic rectocolitis, are pathologies that progress in flare-ups, impacting on patients' quality of life and functional or even vital prognosis. These inflammatory diseases require the use of immunosuppressive and immunomodulatory treatments, the side-effects of which can be significant, and the limited number of which sometimes puts patients and practitioners in a therapeutic impasse from which surgery is the only way out. It is therefore important to be able to develop new therapeutic approaches, ideally better tolerated, that can control inflammation during relapses. Monocytes are one of the main players in the inflammatory reaction. In the laboratory, we have developed a strategy for the metabolic reprogramming of these cells based on the use of oxygen microbubbles to modulate the inflammatory response of monocytes.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women over 18
  • Managed at the CHUGA for a severe IBD flare-up requiring hospitalisation or endoscopy for flare-up
  • Patient not objecting to the REPRO-MICI study

Exclusion criteria

  • Patients protected by law (pregnant or breast-feeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalised under duress).
  • Patients with positive HIV, HBV or HCV serology.
  • Patients with a positive ELISPOT with no history of treatment for latent tuberculosis.

Treatment and study plan

Blood test 4 EDTA tubes

Biological

Blood test 4 EDTA tubes for biological check-up

Primary outcomes

  1. Comparaison of reduction of concentration of inflammatory cytokines and chemokines in cells treated by oxygen microbubbles vs cells not treated

    Time frame: up to 2 years

    Validation of inhibition of the production of inflammatory cytokines and chemokines by the monocytes treated by oxygen microbubbles

Secondary outcomes

  1. Comparaison of tissue factor expression at the membrane of monocytes treated by microbubbles vs monocytes not treated

    Time frame: up to 2 years

    Inhibition of tissue factor expression at the membrane of treated monocytes

  2. Comparaison of glucose metabolism rate in monocytes treated bu microbubbles vs not treated cells

    Time frame: up to 2 years

    Modulation of glucose metabolism in treated monocytes

Study contacts

Contact information is provided by the study sponsor or research team.

Anna Borowik, PhD

CONTACT

[email protected]

+33476769314

Marianne HUPE, MD PhD

CONTACT

[email protected]

+33446466912

Sponsors and collaborators

Lead sponsor

University Hospital, Grenoble

Other

Collaborators

  • Institute for Advanced Biosciences (IAB), Grenoble

Registry information

Acronym: REPRO-MICI

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Apr 25, 2025
Registry last updated
May 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.